NYSE:BHCPharmaceuticals
The Bull Case For Bausch Health (BHC) Could Change Following Mixed 2025 Results And 2026 Outlook Guidance
In February 2026, Bausch Health Companies reported fourth-quarter 2025 revenue of US$2,796 million and a net loss of US$112 million, alongside full-year 2025 revenue of US$10.27 billion, net income of US$157 million, and a US$145 million goodwill impairment, while also issuing 2026 revenue guidance of US$10.63–US$10.88 billion.
A day later, the company and its OraPharma dental unit marked the 25th anniversary of ARESTIN, currently the only FDA-approved locally applied antibiotic adjunct for...